Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1088 as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors
2022-502288-40-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of MK-1088 and pembrolizumab in Nonhematologic neoplasms and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs), Number of Participants Experiencing Adverse Events (AEs) and 1 more. Started Feb 2023; status: completed.
02
Drugs
MK-1088pembrolizumab
03
Conditions
Nonhematologic neoplasmsmetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2022-502288-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502288-40-00.